On May 1st, the CDC stopped reporting mild and asymptomatic COVID-19 “breakthrough” cases. Supposedly this was “to focus on identifying and investigating only hospitalized or fatal cases due to any cause. This shift will help maximize the quality of the data collected on cases of greatest clinical and public health importance.”
Isn’t the overall effectiveness of the so-called vaccines of great clinical importance? It is curious to note that the Delta variant was just beginning to cause a surge in infections then. Wouldn’t it have been of great clinical importance to know how the vaccinated were faring against Delta?
The FDA announced the resignations of two top vaccine officials at the end of August. The reason? Dr. Marion Gruber, the director of the FDA’s Office of Vaccines Research and Review, and her deputy, Dr. Philip Krause, were leaving because of the Biden administration’s plan to roll out COVID-19 booster shots before officials had a chance to approve it.
Not unheard of but these are government employees pushing back against a political agenda.
On Friday the FDA’s Vaccines and Related Biological Products Advisory Committee voted 16-2 AGAINST booster shots for most Americans. At the start of the review process the chair determined that data from outside the country would be allowed as testimony. Some had argued for only data from the US. Why? Are other countries like Israel and Great Britain unable to supply quality data?
This was a stunner. The administration had assumed approval was a foregone conclusion. They had to hustle out St. Fauci to do damage control on the Sunday morning shows.
What happened here? Why did the FDA get a backbone all of a sudden?
Project Veritas released Part 1 of a series of whistleblower stories about problems with the “vaccines.” How many parts there are is unclear.
Could this be the reason for the FDA’s reluctance to do the bidding of the administration and Big Pharma? Just how safe or unsafe are the “vaccines?”